Machine Bio seeks to fundamentally change how biotechs make protein

June 27, 2022

Protein purification is one of the biggest bottlenecks for biotechnology companies. However, startup Machine Bio is developing a next-generation protein synthesis platform that can produce pure protein from DNA in hours, minutes, or continuously using a single step process.

Machine Bio's synthetic biology approach to bioprocessing is based on standalone transmembrane synthesis reactors that can efficiently convert DNA to pure protein. The cell-free reactions occur using a proprietary membrane that recognizes when a desired protein product is produced with an extremely high degree of selectivity.

"We are for the first time putting selective transport into the form of a synthetic membrane that you can build into a bioreactor. This is what allows us to make protein that is born pure. You don't have to subtract impurities from this protein when you make it," said David Marash, co-founder and CEO of Machine Bio. "Downstream purification is such a massive burden for the biopharma industry, a limiting factor, and we looked to nature and found a solution."

Marash and Jack Fernandes, co-founder and head of sales and corporate development, spoke to ScienceBoard.net at the 2022 Biotechnology Innovation Organization (BIO) International Convention in San Diego about the traditional challenges of producing protein for the industry.

"We are challenging a conventional paradigm immediately from the outset," said Fernandes, who described the current protein production process as laborious, time-consuming, and costly. "Previous systems are not operating under the assumption that protein is pure to begin with. That's unique to Machine Bio."

In October, Machine Bio was named the inaugural $200,000 grand prize winner of the BioTools Innovator Competition, selected by a live audience vote at the BioTools Innovator 2021 Capstone Event.

Watch the video below to learn more.


How one CDMO is navigating the global supply chain disruption
The COVID-19 pandemic has disrupted supply chains and production schedules around the world, forcing contract development and manufacturing organizations...
NIH seeks industry partners for technology transfer
The National Institutes of Health (NIH) is the world’s largest public funder of biomedical research. ScienceBoard.net spoke with Michael Salgaller...
A case study on partnering between patient advocacy organizations and biotech
Last week's 2022 Biotechnology Innovation Organization (BIO) International Convention in San Diego gave patient advocacy organizations and biotech companies...
Estonia’s ambitious plans to grow its biotech industry
The Baltic state of Estonia's biotech industry is expected to grow tenfold this decade and offers significant opportunities for Estonian companies. ScienceBoard.net...
Using the power of plants to develop novel biopharmaceuticals
Biologics manufacturing company iBio is using plants as bioreactors to develop and manufacture therapeutics and vaccines. ScienceBoard.net spoke...
Fauna Bio leverages animal genomics, hibernation biology to target human diseases
Biotech company Fauna Bio is leveraging animal genomics and hibernation biology to develop novel translational therapeutics for disease prevention and...
Overcoming the challenges of off-the-shelf allogeneic cell therapies
Chimeric antigen receptor T-cell therapy has emerged as one of the major breakthroughs in cancer immunotherapy in the last decade. In a video interview...
Apeiron Biologics' spinout invIOs targets solid tumors with novel cell therapy platform
Apeiron Biologics' spinout invIOs has a proprietary cell therapy platform for the modulation of intracellular immuno-oncology targets that enables rapid...
Struggle to include women in clinical trials continues despite gains
Though female participation in clinical trials has been steadily improving over the years, most of the women enrolled in trials are white and not members...
Patient advocacy organizations look to partner with pharma companies
Patient advocacy organizations are looking to partner with pharmaceutical companies, offering resources and expertise to maximize the impact and efficiency...
How to develop a sustainable portfolio for cell, gene therapy platforms
Michael Retterath, a Biotechnology Innovation Organization International Convention 2022 panelist and chief business officer at Spark Therapeutics, spoke...
Biotech industry execs, not scientists, remain male-dominated
A panel at the 2022 Biotechnology Innovation Organization International Convention will explore how to close the gender gap in the biotech industry and...
The ‘voice of the patient’ needs to be heard in clinical trials: study
Patient recruitment and retention are among the biggest challenges facing clinical research, particularly in studies targeting rare diseases that have...
New era of non-viral DNA-delivered gene therapy seen emerging
Advancements in nucleic acid-encoded therapeutics over the past decade have sparked the emergence of a new era in non-viral DNA-delivered gene therapy,...
Biotech innovator recounts decades-long journey to create drug discovery technology
Dr. Stan Crooke, PhD, founder, chairman, and chief executive officer of RNA therapy company Ionis Pharmaceuticals, pioneered development of the antisense...
Biotech industry to gather at BIO International Convention in San Diego
More than 11,000 attendees from around the globe will be in San Diego, June 13-16, for the 2022 Biotechnology Innovation Organization (BIO) International...

Copyright © 2022 scienceboard.net

Last Updated 7/20/2022 2:29:24 PM